脓毒症与脓毒性休克患者的液体复苏管理:一项网状Meta分析
该网状Meta分析检索了截至2024年9月的PubMed、Cochrane Central、Embase和Web of Science数据库,纳入28项随机对照试验、共8770例脓毒症或脓毒性休克患者,比较不同液体复苏策略对并发症、治疗反应和结局的影响。结果显示,平衡晶体液在降低90天死亡率方面优于低分子量羟乙基淀粉(RR -0.84;95% CrI [0.75, 0.95])和生理盐水(RR -0.89;95% CrI [0.81, 0.97])。平衡晶体液在减少28天死亡率、肾脏替代治疗需求、输血需求和90天死亡率方面SUCRA排名最高;高渗白蛋白在减少急性肾损伤发生率方面SUCRA排名最高。作者认为平衡晶体液在脓毒症和脓毒性休克患者的液体复苏中具有显著的临床潜力。
要点
- 平衡晶体液降低90天死亡率优于低分子量羟乙基淀粉(RR -0.84;95% CrI [0.75, 0.95])和生理盐水(RR -0.89;95% CrI [0.81, 0.97])。
- 平衡晶体液在减少28天死亡率(SUCRA=71.4%)、肾脏替代治疗需求(SUCRA=75.5%)、输血需求(SUCRA=72.2%)和90天死亡率(SUCRA=86.3%)方面排名最高。
- 与高分子量羟乙基淀粉相比,平衡晶体液与肾脏替代治疗需求减少相关(RR -0.59;95% CrI [0.3, 0.99])。
- 高渗白蛋白在减少急性肾损伤发生率方面最有效(SUCRA=74.5%)。
- 共纳入28项随机对照试验、8770例脓毒症或脓毒性休克患者。
适用人群与场景
- 脓毒症或脓毒性休克患者,来自28项随机对照试验共8770例。
研究设计与关键结果
- 研究类型:网状Meta分析,纳入28项随机对照试验,共8770例脓毒症或脓毒性休克患者。
- 主要结果:平衡晶体液降低90天死亡率优于低分子量羟乙基淀粉(RR -0.84;95% CrI [0.75, 0.95])和生理盐水(RR -0.89;95% CrI [0.81, 0.97])。
- 并发症:与高分子量羟乙基淀粉相比,平衡晶体液与肾脏替代治疗需求减少相关(RR -0.59;95% CrI [0.3, 0.99])。
- SUCRA排名:平衡晶体液在减少28天死亡率(SUCRA=71.4%)、肾脏替代治疗需求(SUCRA=75.5%)、输血需求(SUCRA=72.2%)和90天死亡率(SUCRA=86.3%)方面排名最高;高渗白蛋白在减少急性肾损伤发生率方面排名最高(SUCRA=74.5%)。
证据类型、等级与局限
- 证据类型:网状Meta分析,纳入28项随机对照试验。
- 质量评价:使用Risk of Bias 2工具评估研究质量。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为平衡晶体液在脓毒症和脓毒性休克患者的液体复苏中具有显著的临床潜力,在降低死亡率方面优于低分子量羟乙基淀粉和生理盐水。
- 作者认为高渗白蛋白在减少急性肾损伤方面最有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fluid resuscitation is a cornerstone intervention for patients with sepsis. This network meta-analysis aimed to compare various fluid resuscitation strategies on complications, treatment responses, and outcomes in patients with sepsis or septic shock.
METHODS: PubMed, Cochrane Central Register of Controlled Trials, Embase, and Web of Science were comprehensively searched for records available up to September 2024. Studies were screened and data were extracted based on preset inclusion and exclusion criteria. The quality of studies was evaluated via the Risk of Bias 2 tool. Data analyses were done in Stata18 MP and R 4.4.1.
RESULTS: 28 randomized controlled trials were recruited, encompassing 8770 patients. Balanced crystalloids (BC) demonstrated superior efficacy over low molecular weight hydroxyethyl starch (L-HES) (RR -0.84; 95 % CrI [0.75, 0.95]) and saline (RR -0.89; 95 % CrI [0.81, 0.97]) in reducing 90-day mortality. In terms of complications, BC was linked with a reduced need for renal replacement therapy (RRT) (RR -0.59; 95 % CrI [0.3, 0.99]) compared to high molecular weight hydroxyethyl starch (H-HES). BC ranked highest in reducing 28-day mortality (SUCRA = 71.4 %), demand for RRT (SUCRA = 75.5 %), blood transfusion (BT) (SUCRA = 72.2 %), and 90-day mortality (SUCRA = 86.3 %). Hyperoncotic albumin (Hyper-Alb) was most effective in reducing the incidence of acute kidney injury (AKI) (SUCRA = 74.5 %).
CONCLUSION: BC holds significant clinical potential for fluid resuscitation in patients with sepsis and septic shock. It outperforms both L-HES and saline in reducing mortality among these patients, while Hyper-Alb is most effective in mitigating renal injury.
参考来源
- Long J, Chen Z, Luo X, et al. Fluid resuscitation management in patients with sepsis and septic shock: a network meta-analysis. Am J Emerg Med. 2025. PMID: 40540789. doi:10.1016/j.ajem.2025.06.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。